|Dr. Vicente J. Anido Jr.||CEO & Chairman||1.16M||11.84M||1953|
|Mr. Thomas A. Mitro||Pres & COO||621k||10.85M||1958|
|Dr. Casey C. Kopczynski||Co-Founder & Chief Scientific Officer||578.03k||169.56k||1961|
|Mr. Richard James Rubino CPA||CFO, Sec. & Treasurer||631.12k||N/A||1958|
|Mr. John W. LaRocca Esq.||Gen. Counsel & Assistant Sec.||521.07k||N/A||1965|
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Aerie Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 7.